Veru Inc. received FDA regulatory clarity for enobosarm in combination with GLP-1 RA after successful Phase 2b QUALITY study results. The company plans to start the Phase 2 PLATEAU clinical study in Q1 2026. Following a public offering, they raised approximately $23.4 million. The Phase 2b QUALITY study showed that enobosarm preserves lean mass and leads to greater fat loss with GLP-1 RA. The Phase 2b PLATEAU study will focus on incremental weight loss in older patients with obesity. Overall, the company’s financial results for fiscal year 2025 showed increased research and development expenses but decreased operating losses.

Read more at GlobeNewswire: Veru Reports Fiscal Year 2025 Financial Results and